ASP8825
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Restless Legs Syndrome
Conditions
Restless Legs Syndrome
Trial Timeline
Dec 1, 2007 → Apr 1, 2009
NCT ID
NCT02658188About ASP8825
ASP8825 is a phase 3 stage product being developed by Astellas Pharma for Restless Legs Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT02658188. Target conditions include Restless Legs Syndrome.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02632331 | Phase 1 | Completed |
| NCT02629224 | Phase 1 | Completed |
| NCT02658188 | Phase 3 | Completed |
Competing Products
20 competing products in Restless Legs Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Gabapentin enacarbil | Astellas Pharma | Approved | 85 |
| Regnite | Astellas Pharma | Pre-clinical | 23 |
| ASP8825 + Placebo | Astellas Pharma | Phase 2 | 52 |
| Placebo + Gabapentin enacarbil | Astellas Pharma | Approved | 85 |
| Apomorphine Sublingual Film + Placebo | Sumitomo Pharma | Approved | 85 |
| Suvorexant | Merck | Approved | 85 |
| Cabergoline | Pfizer | Phase 3 | 76 |
| Placebo + pregabalin + pregabalin | Pfizer | Phase 3 | 76 |
| placebo + Pregabalin + Pregabalin + Pregabalin + Pregabalin + Pregabalin | Pfizer | Phase 2 | 51 |
| pregabalin + placebo + pramipexole | Pfizer | Phase 3 | 76 |
| placebo and pregabalin + pramipexol + pramipexol + Pregabalin + pramipexol + pramipexol | Pfizer | Phase 3 | 76 |
| cabergoline + levodopa | Pfizer | Phase 3 | 76 |
| Rotigotine | UCB | Phase 3 | 74 |
| Neupro® | UCB | Pre-clinical | 20 |
| Rotigotine Nasal Spray | UCB | Phase 2 | 49 |
| Rotigotine | UCB | Phase 3 | 74 |
| Levetiracetam (Keppra) | UCB | Phase 2 | 49 |
| Rotigotine + Placebo | UCB | Approved | 82 |
| Rotigotine | UCB | Phase 2 | 49 |
| Rotigotine | UCB | Phase 3 | 74 |